These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17172122)

  • 41. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival.
    Loiseau P; Busson M; Balere ML; Dormoy A; Bignon JD; Gagne K; Gebuhrer L; Dubois V; Jollet I; Bois M; Perrier P; Masson D; Moine A; Absi L; Reviron D; Lepage V; Tamouza R; Toubert A; Marry E; Chir Z; Jouet JP; Blaise D; Charron D; Raffoux C
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):965-74. PubMed ID: 17640601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolongation of cardiac allograft survival by syngeneic hematopoietic stem/progenitor cell transplantation in mice.
    Li J; Meng X; Tao K; Dou K
    Adv Ther; 2008 Sep; 25(9):935-42. PubMed ID: 18758696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic HLA mismatched/ haploidentical hematopoietic stem cell transplantation].
    Wu JY; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):73-7. PubMed ID: 17650664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P; Miklos S; Olkiewicz KM; Müller G; Andreesen R; Holler E; Cooke KR; Hildebrandt GC
    Exp Hematol; 2007 Jan; 35(1):155-63. PubMed ID: 17198884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantations.
    Gassas A; Sung L; Saunders EF; Doyle J
    Bone Marrow Transplant; 2007 Nov; 40(10):951-5. PubMed ID: 17873916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation.
    Mabed M; Maroof S; Zalta K; El-Awadee M
    Bone Marrow Transplant; 2005 Apr; 35(8):803-6. PubMed ID: 15723080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylaxis of graft-versus-host disease by lentiviral-mediated expression of herpes simplex virus-thymidine kinase and ganciclovir treatment.
    Xu K; Zhu F; Du B; Gao F; Cheng H; Pan X
    Transplant Proc; 2008 Oct; 40(8):2665-9. PubMed ID: 18929831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice.
    Cao D; Hu L; Wang Y; Wang L; Zheng W; Ma W
    Transpl Immunol; 2009 Mar; 20(4):243-8. PubMed ID: 19010415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Human herpesvirus 7 infection in patients after allogeneic hematopoietic stem cell transplantation].
    Wang LR; Dong LJ; Lu DP
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2113-6. PubMed ID: 17988530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Marrow graft rejection by repeated transfusions of allogeneic donor spleen cells.
    Xu LH; Fang JP; Huang WG; Xu HG; Weng WJ; Kao GS; Le Y
    Bone Marrow Transplant; 2007 Oct; 40(7):691-8. PubMed ID: 17660838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A murine model of graft-vs-host disease after in utero hematopoietic cell transplantation.
    Misra MV; Gutweiler JR; Suh MY; Twark CM; Valim C; Perez-Atayde A; Kim HB
    J Pediatr Surg; 2009 Jun; 44(6):1102-7; discussion 1107. PubMed ID: 19524724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glutamine protects mice from acute graft-versus-host disease (aGVHD).
    Song EK; Yim JM; Yim JY; Song MY; Rho HW; Yim SK; Han YH; Jeon SY; Kim HS; Yhim HY; Lee NR; Kwak JY; Sohn MH; Park HS; Jang KY; Yim CY
    Biochem Biophys Res Commun; 2013 May; 435(1):94-9. PubMed ID: 23624505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.
    Sun K; Li M; Konopleva M; Konoplev S; Stephens LC; Kornblau SM; Frolova O; Wilkins DE; Ma W; Welniak LA; Andreeff M; Murphy WJ
    Biol Blood Marrow Transplant; 2007 May; 13(5):521-9. PubMed ID: 17448911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.